Oncolytic virotherapy for the treatment of pediatric brainstem gliomas

Area of Science:

• Neuro-oncology
• Pediatric oncology
• Immunotherapy

Background:

• Diffuse intrinsic pontine glioma (DIPG) is a highly lethal pediatric brain tumor with poor prognosis.
• Current treatments, including radiotherapy, offer limited long-term survival and significant neurological morbidity.
• Oncolytic immunovirotherapy presents a novel therapeutic strategy for challenging brain tumors.

Purpose of the Study:

• To evaluate the safety and efficacy of intratumoral Delta-24-RGD oncolytic adenovirus in pediatric patients with newly diagnosed DIPG.
• To assess the feasibility of administering Delta-24-RGD prior to standard radiotherapy.
• To explore the biological activity and immune response induced by Delta-24-RGD in DIPG.

Main Methods:

• A first-in-human phase 1 clinical trial was conducted.
• Pediatric patients with newly diagnosed DIPG received intratumoral injection of Delta-24-RGD.
• Treatment was administered prior to standard radiotherapy.

Main Results:

• The intratumoral delivery of Delta-24-RGD was feasible and demonstrated an acceptable safety profile.
• Encouraging preliminary efficacy signals were observed in pediatric DIPG patients.
• Correlative analyses confirmed the biological activity of Delta-24-RGD within the DIPG tumor microenvironment.

Conclusions:

• Intratumoral Delta-24-RGD oncolytic virotherapy is a safe and feasible approach for newly diagnosed pediatric DIPG.
• The treatment shows encouraging efficacy, warranting further investigation in advanced trials.
• Exploring oncolytic virus potential is crucial for managing devastating pediatric brain tumors like DIPG.